Since FRβ is only highly expressed in leukemia, lymphomas, and the tumor-associated macrophages (TAM) in NSCLC, liver, breast, and brain cancers (Shen et al., 2015), these facts highlight the potential of 3A102 VH for targeting against the TAMs of NSCLC and other cancers as well. This evidence concerns the gene FOLR2 and brain cancer.